Focused on Hematology,
Dedicated to Patients
Disc Medicine has merged with
Gemini Therapeutics and is now
trading on Nasdaq as IRON


Innovation
learn more about our science




Inspiration
learn more about our teamIn The News
Disc Medicine to Participate in the Jefferies Healthcare Conference
WATERTOWN, Mass., May 31, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and…
read more
Disc Medicine Reports First Quarter 2023 Financial Results and Provides Business Update
Two ongoing Phase 2 studies of bitopertin in EPP; initial safety and efficacy data from open-label BEACON trial to be presented at…
read more
Disc Medicine Announces Presentation of Initial Data from Phase 2 BEACON Trial in Patients with Erythropoietic Protoporphyria (EPP) at European Hematology Association (EHA) 2023 Congress
WATERTOWN, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and…
read more